Salix Pharmaceuticals Announces Conference Call; Conference Call Scheduled for 8:00 a.m. ET, Monday, October 11.RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SLXP) will host a conference call at 8:00 a.m. ET on Monday, October 11, 2004 to provide a forum for leading hepatologists to discuss the characteristics of a gut specific antibiotic antibiotic, any of a variety of substances, usually obtained from microorganisms, that inhibit the growth of or destroy certain other microorganisms. Types of Antibiotics and the use of antibiotic therapy in their clinical practice. Salix is pleased to announce the following experts as participants in a panel discussion entitled en·ti·tle tr.v. en·ti·tled, en·ti·tling, en·ti·tles 1. To give a name or title to. 2. To furnish with a right or claim to something: :
"Perspectives in Hepatology: Characteristics of a Gut Specific
Antibiotic and the Use of Antibiotic Therapy in Clinical Practice."
Carroll B. Leevy, M.D.
Associate Professor of Medicine
Associate Director of Clinical Hepatology
The New Jersey Medical School Liver Center
Sammy Davis Jr. National Liver Institute
Kevin D. Mullen, M.D.
Professor of Medicine
Case Western Reserve University
Consultant Hepatologist/Staff Gastroenterologist
Director, Gastroenterology Fellowship Program
MetroHealth Medical Center
F. Fred Poordad, M.D.
Assistant Professor of Medicine
Director of Hepatology and Liver Transplantation
Cedars-Sinai Medical Center
UCLA School of Medicine
Interested parties may access the conference call by way of web cast or telephone. The live web cast will be available at http://www.salix.com. The web cast will be archived on the Company's web site through October 24. The telephone numbers to access the conference call are (800) 263-8506 (U.S. and Canada) or (719) 457-2681 (international). The access code for the call is 967978. A replay of the call will be available from 11:00 a.m. ET, October 11, through October 24. The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international). The access code for the replay is 967978. Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina For other uses of this name, see Raleigh. Raleigh (IPA: /ˈrɑli/, ral-ee) is the capital of the State of North Carolina and the county seat of Wake County. , develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases gastrointestinal disease, n an abnormal state or function of the GI system. . Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's 100-member gastroenterology gastroenterology Medical specialty dealing with digestion and the digestive system. In the 17th century Jan Baptista van Helmont conducted the first scientific studies in the field; William Beaumont published his own observations in 1833. specialty sales and marketing team. Salix markets COLAZAL(R), XIFAXAN(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). A granulated gran·u·late v. gran·u·lat·ed, gran·u·lat·ing, gran·u·lates v.tr. 1. To form into grains or granules. 2. To make rough and grainy. v.intr. mesalamine product also is under development. Salix trades on the Nasdaq National Market under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors "SLXP". Please Note: This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include market acceptance for products, our reliance on our first few products including specifically COLAZAL and XIFAXAN, intellectual property risks, management of rapid growth, and the need to acquire additional products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion